Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 6,033
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
Polycarp Omara
ID: UNCST-2022-R011110
 INSTRUCTIONAL SUPERVISION AND TEACHER COMPETENCE ENHANCEMENT IN SECONDARY SCHOOLS IN ARUA, UGANDA
REFNo: SS1598ES

To propose teacher competence profile for secondary school teachers in Uganda.,To examine the relationship between non-directive supervision and teacher competence enhancement in secondary schools in greater Arua.,To examine the relationship between collaborative supervision and teacher competence enhancement in secondary schools in greater Arua.,To establish the relationship between directive supervision and teacher competence enhancement in secondary schools in greater Arua. ,To explore the status of teacher competence in secondary schools in Arua, Uganda.,To establish the different dimensions of instructional supervision employed in secondary schools in Arua, Uganda.,This study aims to explore the impact of instructional supervision on the enhancement of teacher competence in secondary schools in Arua, Uganda.,
 Uganda 2023-02-13 11:12:24 2026-02-13 Social Science and Humanities Non-Clinical Trial Degree Award
Maxensia owor
ID: UNCST-2021-R014003
 IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age. Version 1.0, 22 September 2022. DAIDS study protocol ID: 38932
REFNo: HS2599ES

iii. Cohort 2: To describe the maintenance of viral suppression and immunologic activity of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),iv. Cohort 2: To describe HIV-1 genotypes and phenotypes for children who experience virologic failure during 48 weeks of CAB + RPV (oral and injectable) or during 44 weeks of CAB LA + RPV LA (injectable only),ii. Cohort Cohort 2: To describe the safety and repeat-dose pharmacokinetics of 48 weeks of CAB + RPV (oral and injectable) or 44 weeks of CAB LA + RPV LA (injectable only),i. Cohort 2: To describe tolerability and acceptability of 48 weeks of CAB + RPV (oral and injectable) and 44 weeks of CAB LA + RPV LA (injectable only),ii Cohort 1: To assess the safety of the oral lead-in of CAB + RPV, and the safety of CAB + RPV (oral and injectable) through Week 24,i.Cohort 1: To describe the repeat-dose pharmacokinetics of CAB + RPV (oral and injectable) through Week 24,
 Uganda 2023-02-13 11:10:13 2026-02-13 Medical and Health Sciences Clinical Trial Non-degree Award
Josphat Muchangi Martin
ID: UNCST-2022-R010507
 Impact of the intervention ‘Financial Inclusion Improves Sanitation and Health 2022-2024’. A randomized controlled trial in Kenya and Uganda
REFNo: SS1587ES

To determine the cost-effectiveness of the FINISH model (creating earning opportunities, job market participation) and amount of leverage funds generated. ,To explore the perspectives, attitudes, and practices of various stakeholders (communities, governments, entrepreneurs, and financiers) regarding the FINISH model.,To estimate the impact of the FINISH model on health (diarrhoea occurrence, hygienic behaviour) and social (school attendance, sanitation) outcomes. ,To evaluate the impacts of the FINISH interventions in Kenya and Uganda.,
 Kenya 2023-02-13 11:06:11 2026-02-13 Social Science and Humanities Non-Clinical Trial Non-degree Award
Denis Bwayo
ID:
Risk factors, genetics and mortality among patients with dilated cardiomyopathy in Uganda
REFNo: HS2444ES

1. To investigate risk factors, genetics, and moratlity among patients diagnosed with DCM in Uganda Delete
2.To determine the underlying genetics and inheritance characteristics of DCM in Uganda Delete
3. To determine the incidence and predictors of all-cause mortality 12 months after DCM diagnosis in Uganda
 Uganda 2023-02-13 11:04:24 2026-02-13 Medical and Health Sciences Non-Clinical Trial Degree Award
Victoria Nankabirwa
ID: UNCST-2021-R011871
 Use of the Global Scale for Early Development (GSED) within Preventing Infant Malnutrition with Early Supplementation (PRIMES) Trial
REFNo: HS2263ES

1) To obtain preliminary estimates of the correlation between Global Scale for Early Development (GSED) scores and MRI findings (total brain and white matter volumes) in infants at 6 and 12 months of age.
2) To assess user feedback about the Hyperfine LF MRI device.
3) To determine whether the Hyperfine LF MRI device is feasible and acceptable among healthcare personnel and caregivers of infants undergoing LF MRI.

 Uganda 2023-02-13 11:01:02 2026-02-13 Medical and Health Sciences Non-Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS